Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to race: post-hoc analysis from double-blind combined BIPARK-I and II data.
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…Deep Brain Stimulation in Early-Stage Parkinson’s Disease Provides Long-Term Rest Tremor Benefit Through Five Years
Objective: To analyze symptomatic control of rest tremor five years after randomization in the deep brain stimulation (DBS) in early-stage Parkinson’s disease (PD) pilot clinical…Gocovri Dose Adjustment in Elderly Parkinson’s Patients at Risk for Renal Impairment: Implications from an Exposure Simulation Model
Objective: Evaluate amantadine exposure following Gocovri® (amantadine) extended release capsules dosing regimens in renal impairment, using pharmacokinetic (PK) modeling and simulations. Background: Gocovri bedtime dosing…Practice Patterns with Onabotulinum Toxin-A for Movement disorders: South Asian Neurologist Survey
Objective: To understand physicians’ barriers in management of movement disorders (MD) with Onabotulinumtoxin-A (OnabotA). Background: OnabotA effectiveness for treating MD is well known. However, from…Hemiballismus-hemichorea due to ischemic stroke
Objective: Describe an unsual cause of movements disorders . Background: Hemiballismus-hemichorea is a rare and debilitating presentation of subcortical stroke. Method: We describe a case…Open-Label Study of Pimavanserin Patients With Comorbid Parkinson’s Disease and Depression
Objective: We are assessing use of pimavanserin (PIM) for treatment of depression in adults with PD. Background: Depression occurs in ~50% of Parkinson’s disease (PD)…Outcomes of the first-in-human study with a recombinant botulinum toxin E (rBoNT-E): safety and pharmacodynamic profile of rBoNT-E compared with abobotulinumtoxinA
Objective: To evaluate safety and pharmacodynamic (PD) profiles of the first recombinant botulinum toxins (BoNT) serotype E (rBoNT-E) versus abobotulinumtoxinA (aboBoNT-A) in healthy male volunteers.…Influence of baseline OFF-time in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the impact of baseline OFF-time on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: OPC,…An open-label, 1-year extension clinical study in Japan of Opicapone treatment for Parkinson’s disease -Comfort-PD study part 2
Objective: To investigate the safety and efficacy of continuous treatment with 50 mg Opicapone (OPC) for 1 year after treatment with a placebo, 25 mg…INTREPID: A 2-Year Follow-Up of a Prospective, Double Blinded, Multi-Center Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant-Current Rechargeable System for Treatment of Parkinson’s Disease
Objective: The objective of the INTREPID clinical trial assessed improvement in motor function and quality of life in patients with advanced, levodopa responsive Parkinson's disease…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 217
- Next Page »